Evaxion A/S (EVAX) Form 6-K — Aug 20, 2026
Evaxion A/S reported second quarter 2026 financial results in line with expectations, with a net loss of $3.7 million, narrowed from $4.8 million in the second quarter of 2025, driven primarily by lower capital market transaction costs and reduced financial expenses from a smaller derivative liability. The clinical-stage TechBio expanded its R&D pipeline with EVX-05, a novel off-the-shelf therapeutic cancer vaccine for glioblastoma developed partly with Duke University School of Medicine, and will present three-year clinical data for lead asset EVX-01 at the ESMO Congress 2026 in October.
Key figures
- Eps
- -$0.01 (basic and diluted, Q2 2026)
- Revenue
- 0 (nil for Q2 2026)
- Net Income
- -$3.7 million (Q2 2026 net loss)
- Total Assets
- $19.4 million (as of June 30, 2026)
- Cash Position
- $14.0 million (as of June 30, 2026)
- Shares Outstanding
- 417010756
- Shares yoy
- 417,010,756 vs 315,828,608 a year ago
- Cash runway
- into second half of 2027
- Q1 2026 net loss
- $3.6 million
- Q2 2025 net loss
- $4.8 million
- Cash march 31 2026
- $18.4 million
- Ga expenses q2 2026
- $1.5 million
- Rnd expenses q2 2026
- $2.3 million
- Cash december 31 2025
- $23.2 million
- Six month 2026 net loss
- $7.4 million
- Total equity june 30 2026
- $9.5 million
- Net financial expense q2 2026
- $0.1 million
- Total equity december 31 2025
- $17.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.